Dew, it is erroneous to refer to aab-001 as a candidate for Glaucoma. In fact aab-001 is just the designation of the anti-body in the Wyeth-Elan agreement addressing Alzheimer's. Instead the correct term is Bapineuzumab, as the anti-body is named. I will post a correction with a superior link in order to supercede your error.
Market Data 
Markets
AI
